PICO Portalanswers from OpenAlex
NGM Biopharmaceuticals (United States)
InstitutionResearch output, impact & collaborations
NGM Biopharmaceuticals (United States) is a institution indexed in PICO Portal from OpenAlex.
What is known about NGM Biopharmaceuticals (United States)?
PICO Portalrecord summary
NGM Biopharmaceuticals (United States) is a research organisation in South San Francisco, US. OpenAlex records 616 works and 121,297 citations for it. 211 researchers list it as their most recent affiliation.
How many works does NGM Biopharmaceuticals (United States) have?
PICO Portalindexed works
NGM Biopharmaceuticals (United States) has 616 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does NGM Biopharmaceuticals (United States) have?
PICO Portalcitation count
NGM Biopharmaceuticals (United States) has 121,297 citations in the OpenAlex counts PICO Portal stores.
How many researchers are at NGM Biopharmaceuticals (United States)?
PICO Portalresearcher count
NGM Biopharmaceuticals (United States) has 211 researchers in the PICO Portal index.
What is the average h-index at NGM Biopharmaceuticals (United States)?
PICO Portalavg h-index
NGM Biopharmaceuticals (United States) has an average h-index of 55.5 in OpenAlex.
What is the ROR of NGM Biopharmaceuticals (United States)?
PICO Portalror
The ROR for NGM Biopharmaceuticals (United States) is on the source record.
What is the OpenAlex record for NGM Biopharmaceuticals (United States)?
PICO Portalopenalex
The OpenAlex for NGM Biopharmaceuticals (United States) is on the source record.
Who are the most-cited researchers behind NGM Biopharmaceuticals (United States)?
PICO Portaltop researchers by citations
What are the most-cited papers on NGM Biopharmaceuticals (United States)?
PICO Portalmost cited works
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors
Joshua B. Rubin, Andrew L. Kung, Robyn S. Klein, Jennifer A. Chan, Yanping Sun, Karl Schmidt, Mark W. Kieran, Andrew D. Luster, Rosalind A. Segal
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
Priscilla K. Brastianos, Amaro Taylor‐Weiner, Peter Manley, Robert T. Jones, Dora Dias‐Santagata, Aaron R. Thorner, Michael S. Lawrence, Fausto J. Rodríguez, Lindsay A. Bernardo, Laura Schubert, Ashwini Sunkavalli, Nick Shillingford, Monica L. Calicchio, Hart G.W. Lidov, Hala Taha, Maria Martinez‐Lage, Mariarita Santi, Phillip B. Storm, John Y. K. Lee, James N. Palmer, Nithin D. Adappa, R. Michael Scott, Ian F. Dunn, Edward R. Laws, Chip Stewart, Keith L. Ligon, Mai P. Hoang, Paul Van Hummelen, William C. Hahn, David N. Louis, Adam Resnick, Mark W. Kieran, Gad Getz, Sandro Santagata
Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma
Adam M. Fontebasso, Simon Papillon‐Cavanagh, Jeremy Schwartzentruber, Hamid Nikbakht, Noha Gerges, Pierre Fiset, Denise Béchet, Damien Faury, Nicolas Jay, Lori Ramkissoon, Aoife Corcoran, David Jones, Dominik Sturm, Pascal D. Johann, Tadanori Tomita, Stewart Goldman, Mahmoud G. Nagib, Anne Bendel, Liliana Goumnerova, Daniel C. Bowers, Jeffrey R Leonard, Joshua B. Rubin, Tord D. Alden, Samuel R. Browd, J. Russell Geyer, Sarah Leary, George I. Jallo, Kenneth J. Cohen, Nalin Gupta, Michael D. Prados, Anne‐Sophie Carret, Benjamin Ellezam, Louis Crevier, Álmos Klekner, László Bognár, Péter Hauser, Miklós Garami, John S. Myseros, Zhifeng Dong, Peter M. Siegel, Hayley Malkin, Azra H. Ligon, Steffen Albrecht, Stefan M. Pfister, Keith L. Ligon, Jacek Majewski, Nada Jabado, Mark W. Kieran
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
Solange Peters, Scott Gettinger, Melissa L. Johnson, Pasi A. Jänne, Marina Chiara Garassino, Daniel C. Christoph, Chee‐Keong Toh, Naiyer A. Rizvi, Jamie E. Chaft, Enric Carcereny, Jyoti D. Patel, Laura Q.M. Chow, Marianna Koczywas, Cheryl Ho, Martin Früh, Michel M. van den Heuvel, J. Rothenstein, Martin Reck, Luis Paz‐Ares, Frances A. Shepherd, Takayasu Kurata, Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, Alan Sandler, Enriqueta Felip
How much of the research on NGM Biopharmaceuticals (United States) is open access?
PICO Portalopen access share
83%OPEN ACCESS